Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would be great if Elite was able to drive revenue through international expansion. If Elite is receiving one-time payments, their current portfolio of products is performing even worse since Elite’s revenue performance was flat.
Read the footnotes. These are options awarded. Company leadership hasn’t bought company stock on the open market for several years.
Paid vs revenue accrual are 2 completely different things.
None, other than smaller more flexible funds, but aren’t worth pursuing. This is why company needs to get off OTC and do an R/S and small ongoing buyback beyond just R&D investment. Company has had to reinvent itself multiple times and is about to embark on another one April 1st without Lannett. We may not hear how that transition is being executed until August call for Q1 results.
Apparently didn’t translate to Elite as expected. Sales volume was flat according to Elite’s reporting.
Let’s whip out the bubbly to celebrate mediocrity.
Adderall is the majority if their revenue. Of course the majority of their mfg rev is driven by Adderall. 2 customers counted for 96% of Elite revenue. That is almost entirely Adderall.
Lol
They ALWAYS break down mfg vs licensing rev each and every quarter.
Interesting that Mfg fees were less than last year in period of Adderall shortage. Awesome.
When factoring in inflation, that is a loss in revenue.
There is nothing interesting about it. It’s all contractual including the PPS on which the options are based.
Why would Nasrat take Elite to Nasdaq when their primary drug revenue has significant uncertainty after Lannett agreement termination?
1 billion+ shares outstanding with no interest yet from investment funds is the issue. Company is making strides, but being on OTC will not get us out of this share price rut. All while who gets paid handsomely in shares while the price remains low year after year continuing dilution?
Per the post, clearly the purpose is to audit all items and individuals up Nasrat’s rear.
Considering there is a massive shortage of trailers to use - cost for 3PL is through the roof right now.
But wait, I thought this was launching any day now…
Shareholders have received free spankings out in the shed.
There is no deflection, only selective ignorance from some OTC investors.
Back to my comment on IR basics in doing what a company says it will. This is the cardinal rule in building trust with investors.
Here’s a softball from this year. How many ANDAs did Elite say they will file this year? How many has Elite filed this year or how many are they on track to file by end of next month?
Survey says…let me tally that one for you - zero.
I’m simply much more efficient with my words. Doesn’t take a PhD to realize being verbose without meaning is simply someone wanting to hear themselves talk. (Hint hint)
IR is the only person between investors and C-Suite. There is no one else unless IR team has more than one person. C-Suite or BOD should not be fielding IR questions.
For starters, as I have mentioned many times, effective and trusted leaders do what they say will do. Leaders set a standard and stick to it. They always meet expectations at minimum. Trust is built as expectations are at least met, if not exceeded on a regular basis. This is how confidence is built with investors, lenders, employees, etc. One does not have to search hard to find the many times Elite management has set unrealistic expectations for themselves and completely tripped over that bar.
Lol simply a new username. OTC posters here have been saying NASDAQ for years. CEO has mentioned it several times over the years “when the time is right” to keep OTC investors on the hook.
Successful companies do what they say they will do. This is how confidence within the investment community is built. No need to expound further.
Lol
Like I said, raise of hands for all those who have IR experience. That’s what I thought.
Wasn’t it NASDAQ in 2017?
Not until they can fix their margin issues. The can keeps getting kicked down the road. A plan that can’t be executed is simply a plan. They are becoming a show-me stock. Until margins improve in the financials why trust leadership forecasts if they keep missing them?
Seems like someone falls into that category and is offended. Who all has IR experience at a billion dollar company?
Am I the only one on the board that does?
That’s precisely why you DO NOT communicate in a time of risk. Welcome to the world of communications. Why set the bar high when the bar could get annihilated in 6 months? Welcome to the complex world of investor management.
OTC investors are nothing but armchair quarterbacks that pretend to know everything, yet know nothing.
Why would you be overly optimistic in a PR when the primary revenue stream needs to be replaced within the next 6 months? That makes no sense. Too much is at risk.
What I wouldn’t want to see is Kirkov leaving. That would spell disaster.
This was a PR for the upcoming conference call. Why not wait until the conference call to judge?
Again, Kirkov has absolutely nothing to do with a PR. That’s outside of his swim lane.
Of course they can as long as they make it public. Saying it to one private group of investors would cause an issue.
Kirkov doesn’t write PR’s. That’s typically IR, CFO or CEO.
Most of Elite’s rev is with Adderall. That is tied up until end of March with Lannett. He cannot simply exit this contract. His job will be to execute the bridge to their sales/distribution strategy as seamless as possible. He has very limited products to work with outside Adderall. Once the R&D pipeline shifts more to approvals, then he has more to work with.
Would you reconsider at 0.0356?
It’s a cash flow negative situation when creating your own sales distribution channel. Upfront costs for payback months later. Additional filings now won’t help with the cash flow crunch coming after Lannett deal terminates. Those are next near benefits, if FDA approval process is smooth.
Lannett did fantastic with IR. ER on other hand was pitiful. Company has been able to continue to invest in pipeline and hopefully is starting to move before another round of Covid hits studies, balance sheet is shored up to help weather upcoming transition away from Lannett and we have new chief of sales and CFO. We have some major speed bumps ahead, but think the ship will sail through these rough waters. Seat belts will need to be buckled as there will be some rough spots for sure.
The risk lies in how long it takes to rebuild the upcoming loss of Adderall revenue with Lannett. They can build from scratch or find another distributor, but until that revenue replacement occurs, we have serious risk of a burning cash flow situation. Pipeline isn’t moving fast enough to help offset.
What makes you think he could get 15 cents a share when their major revenue source with Lannett needs to be built from scratch? There’s significant risk here still.
50M is not realistic. 30M annualized will be a stretch goal after they part ways with Lannett since they are going to build sales team from scratch.
Usually it’s a multi year distribution agreement unless during initial ramp months performance is very poor. Gives seller/distributor an out.
Almost to the finish line. Being shelved next to Codeine-acet?